Kornimate/medical-research-clean huggingface dataset:
intensity modulated radiation therapy (imrt) pelvic nodes prostate

Conditions: Adenocarcinoma of the Prostate

Summary: the purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer. all eligible patients with high risk prostate cancer who are going to have primary radiation therapy to the pelvic lymph nodes and prostate seminal vesicles with or without concurrent hormonal therapy will be approached regarding study entry.

prostate cancer is now the most commonly diagnosed cancer in canadian men and is the third most common cause of cancer death.1 locally advanced prostate cancer (clinical t3/t4) is uncommon in north america because of earlier diagnosis following widespread psa testing and patient information campaigns. however, in the past decade the term high-risk prostate cancer has been developed to include the previous locally advanced disease and patient with t1/t2 disease with poor prognostic features (either a high prostate specific antigen or high gleason score). the risk of involvement of pelvic lymph nodes by prostate cancer for certain subgroups of intermediate risk and most high risk prostate cancer may be substantial. the long term results of conventional dose (66-70 gy) external beam radiation therapy for intermediate and locally advanced prostate cancer have been disappointing. the combination of hormonal therapy and radiation therapy or radiation therapy dose escalation are the two strategies which have been evaluated and are now used to improve these results.

Eligibility criteria:
inclusion criteria: * a histologic diagnosis of adenocarcinoma of the prostate within six months of entry. * clinical stage t1-t2 with (psa \>20 or gleason score \>7) * clinical stage t3, t4 * bone scan reported as negative for metastases within 6 months of study entry. * all patients must have a ct scan of the abdomen and pelvis reported as negative for nodal metastases within 12 wks of study entry. * the patient must not have received greater than 6 months of hormonal therapy. * the patient must not have received cytotoxic anticancer therapy prior to study entry. * patients must have an ecog performance status of 2 or less. * age 80 years old or less * signed informed consent exclusion criteria: * patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy * patients with prior colorectal surgery * patients with prior or active malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer

Keywords: imrt treatment for prostate cancer patients radiation treatment for prostate cancer cancer of the prostate patients with high risk adenocarcinoma of the prostate
the effectiveness of neurofeedback for the treatment of chronic pain

Conditions: Chronic Pain

Summary: this study evaluates the effectiveness of neurofeedback (teaching participants to gain control over their own brainwaves) in chronic pain. the study is made up of four pilot studies. participants who take part will undergo the cold pressor test, submerging their hand in cold water in order to simulate chronic pain. brain activity will be measured using electroencephalography (eeg).

chronic pain is a persisting pain which often exists in the absence of detectable tissue damage. it is also associated with feelings of depression, anxiety, and despair. current treatments for chronic pain usually involves drug treatments, which often has unwanted side effects. this study aims to assess the effectiveness of neurofeedback, which refers to teaching participants to gain control over their own brainwaves, as an intervention to treat chronic pain. it is believed that by teaching participants to gain control over a brain signal associated with pain resilience, the participant can reduce some of the negative effects associated with chronic pain. participants who take part in this study will have their brain activity recorded using electroencephalography (eeg), and have pain elicited using the cold pressor test (cpt), which involves the participant submerging their wrist in cold water to elicit a chronic pain-like sensation. this is a safe, regularly used method, and the participant is free to remove their hand early if the pain becomes too great. some participants who take part will undergo neurofeedback training, which will involve them viewing a signal associated with pain resilience, and learning to increase it over multiple sessions.

Eligibility criteria:
inclusion criteria: * willing and able to give informed consent for participation in the study * must be aged 40 or older exclusion criteria: * current or planned hospitalisation during the period of study. * non-english speaking participants * participants already involved in clinical trials, if it is not possible to schedule around this * unable, in the opinion of the research investigator, to comply or adhere to the requirements of the study. * patients with chronic pain in both upper limbs * history of brain injury, stroke or neurosurgical procedures * an implanted neurostimulator (e.g., deep brain stimulator) * damaged skin tissue on the head, or a skin condition such as severe eczema, or any skin allergies * failure of cognitive test (montreal cognitive assessment) will exclude participants from taking part in studies that use neurofeedback procedures * some but not all of the study will be unavailable to participants currently undergoing psychotherapy (such as cognitive behavioural therapy).

Keywords: neurofeedback
deep vein thrombosis treatment with the oral direct factor xa inhibitor rivaroxaban in patients using a strong cyp 3a4 inducer

Conditions: Venous Thrombosis; Deep Vein Thrombosis

Summary: this is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (dvt) or acute pulmonary embolism (pe) who concomitantly use a strong cytochrome p450 isoenzyme 3a4 (cyp 3a4) inducer for the entire 3-month study duration.

the following laboratory variables were determined at baseline at the local laboratories: hemoglobin, platelets, activated partial thromboplastin time (aptt), international normalized ratio (inr), alanine aminotransferase (alt), and creatinine.

Eligibility criteria:
inclusion criteria: * confirmed acute symptomatic proximal deep- vein thrombosis and/or pulmonary embolism * concomitant use of a strong cyp 3a4 inducer, (i.e., carbamazepine, phenytoin, rifampicin/rifampin, and rifabutin) exclusion criteria: * legal lower age limitations (country specific) * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of deep -vein thrombosis and/or pulmonary embolism * other indication for vitamin k antagonist (vka) than deep -vein thrombosis and/or pulmonary embolism * concomitant use of strong cyp3a4 inhibitors (e.g., hiv protease inhibitors, systemic ketoconazole) * use of the strong cyp 3a4 inducers phenobarbital/primidone or st john's wort

Keywords: embolism and thrombosis pulmonary embolism embolism venous thrombosis thrombosis enzyme inducers cyp inducers cohort study pharmacologic actions respiratory tract diseases lung diseases vascular diseases human immunodeficiency virus (hiv) neurologic disease additional relevant mesh terms: fibrin modulating agents anticoagulants therapeutic uses hematologic agents enzyme inhibitors cardiovascular diseases cardiovascular agents
motion sickness rehabilitation for virtual reality

Conditions: Motion Sickness

Summary: the objective of this study was to investigate the effect of a rehabilitation program on motion sickness. a combined rehabilitation program will be given participants who showed motion sickness symptoms.

in the realm of virtual environments and simulators, a significant hurdle that hampers user engagement resides in the manifestation of adverse effects. these deleterious consequences become apparent during prolonged exposure to virtual settings, with approximately 30% of users grappling with symptoms like nausea and up to 40% reporting eyestrain. furthermore, users frequently describe a constellation of other discomforting sensations, including headaches, dizziness or vertigo, compromised postural stability, drowsiness, increased salivation, and perspiration. these adverse effects have been documented in scientific literature under various monikers, with 'cybersickness' and 'motion sickness' (ms) being the most prevalent designations. motion sickness, a vexing symptom characterized by discomfort experienced during movements unrelated to one's bodily motions, such as those encountered during travel by air, sea, or land, lies at the crux of this issue. the pathophysiological elucidation of the mechanisms underlying ms centers around the notion of sensory conflict or sensory mismatch. this conflict arises from disparities between the sensory information derived from kinaesthetic inputs, the vestibular and visual systems, and the sensory patterns engendered by the virtual environment

Eligibility criteria:
inclusion criteria: * having stereoacuity score of 3552 arc/s on the titmus fly test exclusion criteria: * having partial or total vision loss * being diagnosed with vertigo * having previous experience of head mounted virtual reality devices

Keywords: rehabilitation balance reflex
a study comparing etoricoxib and diclofenac sodium in post hallux valgus surgery pain

Conditions: Hallux Valgus; Postoperative Pain

Summary: the investigators hypothesize that cyclooxygenas-ii-selective inhibitors (coxibs) provide a better patients assessed overall satisfaction when used for pain management after elective hallux valgus surgery as compared to traditional non-steroidal anti-inflammatory drugs (nsaids).

the aim of the present study is to compare patients' satisfaction with pain medication during the first 7 first postoperative days following elective hallux valgus surgery in general anaesthesia between etoricoxib and diclofenac in a prospective randomised double-blind study design.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology (asa) physiological class 1-2 patients * aged 18-65 years * scheduled for elective hallux valgus surgery in general anesthesia exclusion criteria: * nsaid allergy * liver disease * renal disease * uncontrolled cardiovascular disease * lithium therapy * chronic pain * regular analgesia use

Keywords: day case surgery postoperative pain nsaids coxibs
beans/bran enriching nutritional eating for intestinal health trial

Conditions: Colorectal Cancer Control and Prevention

Summary: the purpose of this study is to explore the effects of cooked navy bean powder or rice bran consumption on the stool microbiome and metabolome of colorectal cancer survivors and healthy adults.

objectives: 1. to learn about how increased cooked navy bean powders or rice bran dietary intake affect the stool microbiota of colorectal cancer survivors and healthy adults. 2. to determine whether cooked navy bean powders or rice bran consumption modulate microbial metabolism. 3. to observe dietary changes in the blood, urine and stool metabolite profiles and inflammatory cytokines.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * be a colorectal cancer survivor that is a minimum of 4 months post chemotherapy/radiation treatment. or be a healthy adult with no prior history of treatment for cancer. * bmi between 25-35 * no previous or concurrent malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer and other cancer for which the patient has been disease free for five years. * ability to complete questionnaire(s) and dietary food logs * willingness to consume meals/snacks provided for 28 consecutive days * drink less than or equal to one alcoholic drink/day exclusion criteria: * history of food allergies and/or major dietary restrictions * pregnant or lactating or planning to become pregnant * self identified as a smoker * taking prescribed medication to control their lipids * taking bean-o, other anti-flatulence medications or prolonged antibiotic use (one month) * have a history of gallstones.

Keywords: prevention & control diet functional food nutrition assessment oryza sativa rice bran phaseolus vulgaris l. legumes microbiome metabolomics prebiotics
correlation between the severity of coronary artery disease and peripheral arterial stiffness in patients with premature coronary heart disease

Conditions: Premature Coronary Heart Disease

Summary: premature coronary heart disease (chd) refers to the onset of myocardial infarction in men \< 55 years old, women \< 65 years old. at present, researches on early-onset coronary heart disease mostly focus on its risk factors and clinical characteristics, but there is no relevant research on the relationship between early-onset myocardial infarction and atherosclerosis.

premature coronary heart disease is defined as the first onset of male \< 55 years old, female \< 65 years old, confirmed by clinical examination. a number of studies have found that smokers have a significantly increased risk of acute myocardial infarction, and suggest that continued smoking is still an independent predictor of mace. these findings suggest that smoking is significantly associated with early-onset coronary heart disease. a number of studies have found that smoking can increase peripheral arterial stiffness. at present, there is no study on peripheral arterial stiffness in patients with early-onset myocardial infarction, so we suspect that peripheral arterial stiffness in patients with early-onset myocardial infarction is significantly increased

Eligibility criteria:
inclusion criteria: * the onset of coronary heart disease (including acute coronary syndrome and stable angina pectoris) was less than 55 years old in men and 65 years in women exclusion criteria: * non coronary heart disease leading to chest pain (myocarditis, pericarditis, pulmonary embolism, aortic dissection, unstable angina pectoris) definite infection tumor liver and kidney insufficiency autoimmune disease acromegaly hyperthyroidism and subclinical hyperthyroidism secondary hypertension, etc.

Keywords: premature coronary heart disease degree of coronary stenosis arterial stiffness
guo's entry tear repair :the first in man study of endopatch system

Conditions: Chronic Stanford B Type Aortic Dissection Proximal Tear

Summary: a prospective, single-center, first in man study to evaluate the safety and efficacy of endopatch system manufactured by hangzhou endonom medtech co., ltd. for the chronic stanford b type aortic dissection proximal tear.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 80 years old, no gender limitation; 2. able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol; 3. diagnosed as chronic stanford type b aortic dissection; 4. maximum diameter of the intimal tears is between 2mm and 20mm; 5. important branch vessels will not be covered after intimal tears closure; 6. aortic endovascular treatment can be performed with appropriate arterial access. exclusion criteria: 1. diagnosed as acute, subacute aortic dissection; 2. intermural hematoma, aortic ulcer, pseudoaneurysm, and severe aortic calcification; 3. the minimum distance between the intimal tears of the aortic intimal flaps and the root of the intimal flaps is less than the radius of the patch to be used (the patch cannot be deployed flat); 4. pregnant, breastfeeding or cannot contraception during the trial period; 5. participated in clinical trials of other drugs or devices during the same period; 6. the same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.), and the postoperative drug treatment plan is therefore affected; 7. allergic to contrast agents, anesthetics, patches, and delivery materials; 8. cannot tolerate anesthesia; 9. severe liver, kidney, lung, and heart function abnormalities before surgery \[serum creatinine exceeds 2 times the upper limit of normal; alanine aminotransferase (alt) or aspartate aminotransferase (ast) exceeds 5 times the upper limit of normal; serum total bilirubin (stb) more than 2 times the upper limit of normal; left ventricular ejection fraction is lower than normal by cardiac color doppler ultrasound examination\]; 10. history of myocardial infarction, tia or cerebral infarction within the past 3 months; 11. life expectancy is less than 12 months (such as advanced malignant tumors) 12. acute systemic infection 13. investigator judged that not suitable for interventional treatment.
the effect of melatonin and vitamin c on covid-19

Conditions: Covid19; SARS-CoV Infection

Summary: this is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin c on symptoms and outcomes of patients with covid-19.


Eligibility criteria:
inclusion criteria * covid-19 positive test (outpatient testing), * age \>50 (chosen based greater risk for older patients to be vitamin deficient, age \>65 not used so as not to be too restrictive in the inclusion criteria) * experiencing symptoms for \<5 days prior to enrollment * able to read and write in english or spanish * able to access redcap daily * valid email address * current has a lancaster general health primary care physician exclusion criteria * covid-19 test ordered pre-procedure for asymptomatic screening * currently taking vitamin c supplements * currently taking melatonin supplements * currently hospitalized * deceased * currently pregnant * currently incarcerated

Keywords: vitamin c melatonin
relative bioavailability and effect of food study with an oral mini-tablet formulation of filgotinib in healthy subjects

Conditions: Bioavailability

Summary: open label study to assess relative bioavailability of filgotinib oral mini-tablet versus oral tablet formulation and effect of food on the mini-tablet formulation.


Eligibility criteria:
key inclusion criteria: * a body mass index (bmi) between 18.0 and 30.0 kg/m2, inclusive. * judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ecg), and fasting clinical laboratory safety tests. aspartate aminotransferase (ast) and alanine aminotransferase (alt) must be no greater than 1.5x upper limit of normal range (uln) and total bilirubin not greater than uln. other clinical laboratory safety test results must be within the normal ranges or test results that are outside the normal ranges need to be considered not clinically significant in the opinion of the investigator. key exclusion criteria: * known hypersensitivity to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator. * treatment with any medication (including over-the-counter (otc) and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing.
investigating the impact of a shared decision-making tool

Conditions: Osteoarthritis, Knee

Summary: the purpose of this research study is to learn more about how the use of a shared decision-making tool (sdmt) will impact a patient's decision-making to pursue treatment for knee osteoarthritis.

the main purpose of this study is to determine the impact of the sdmt on patient decision- making regarding various treatment modalities for knee osteoarthritis. if the sdmt is found to be beneficial, it can be implemented to help engage patients in their care and support more efficient implementation of treatment suggestions. this subsequently will improve patient's quality of life. getting patients who have not taken advantage of preventive care or healthy lifestyles to change is paramount to making the medical experience in america more equal for all its citizens and reducing total societal costs. building provider-patient communication tools that resonate with all stakeholders should inform patients as they work to make health decisions that reflect their individual beliefs.

Eligibility criteria:
inclusion criteria: * age 45-64 * mild to moderate knee pain consistent with a diagnosis of osteoarthritis exclusion criteria: * known inflammatory disease diagnosis (ex. lupus, sjogren, or rheumatoid arthritis, prior knee replacement, acute knee trauma) * bmi over 45 * persons from vulnerable populations
entospletinib monotherapy and in combination with chemotherapy in adults with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: this study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (aml).


Eligibility criteria:
key inclusion criteria: * adults with aml in need of treatment * group a : individuals ≥ 18 years of age with previously untreated aml by world health organization (who) criteria who are able and should receive up to 2 cycles of induction chemotherapy with 7+3 as determined by the treating physician * group b: individuals \> 70 years of age with previously untreated aml by who criteria; or individuals ≤ 70 years of age with previously untreated aml who refuse or are unable to receive chemotherapy with 7+3 as determined by the treating physician * group c: individuals ≥ 18 years of age with relapsed/refractory aml by who criteria; or with relapsed/refractory aml with mixed-lineage leukemia (mll); or with previously untreated aml by who criteria and who would have met disease eligibility criteria for group a or b but refuse or are unable to receive chemotherapy and hypomethylating agent as determined by the treating physician key exclusion criteria: * known active central nervous system or leptomeningeal lymphoma * subjects with acute promyelocytic leukemia (m3) * treatment with proton pump inhibitors (ppis) within 7 days prior to enrollment. note: other protocol defined inclusion/ exclusion criteria may apply.